Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel Free ALVR Stock Alerts

AlloVir (ALVR) Financials

AlloVir logo
$2.50 -0.06 (-2.34%)
As of 10/8/2026
Compare
Annual Income Statements for AlloVir

Annual Income Statements for AlloVir

This table shows AlloVir's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -24 -70 -172 -169 -190 -69 -43
Consolidated Net Income / (Loss)		 -24 -70 -172 -169 -190 -69 -43
Net Income / (Loss) Continuing Operations		 -24 -70 -172 -169 -190 -69 -43
Total Pre-Tax Income 		-24 -70 -171 -169 -191 -69 -43
Total Operating Income		 -27 -71 -170 -171 -200 -52 -46
Total Gross Profit		 0.17 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.17 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 27 71 170 171 200 52 46
Selling, General & Admin Expense		 11 22 49 52 48 6.69 15
Research & Development Expense		 16 50 121 119 133 45 31
Total Other Income / (Expense), net		 2.86 1.53 -1.14 2.23 9.36 -17 2.75
Other Income / (Expense), net		 0.80 0.20 -2.45 0.35 3.62 -15 2.75
Basic Earnings per Share		 ($18.54) ($2.59) ($2.74) ($2.20) ($42.09) ($51.77) ($2.85)
Weighted Average Basic Shares Outstanding		 1.29M 26.90M 62.78M 76.65M 4.52M 1.34M 15.27M
Diluted Earnings per Share		 ($18.54) ($2.59) ($2.74) ($2.20) ($42.09) ($51.77) ($2.85)
Weighted Average Diluted Shares Outstanding		 1.29M 26.90M 62.78M 76.65M 4.52M 1.34M 15.27M
Weighted Average Basic & Diluted Shares Outstanding		 1.29M 26.90M 62.78M 93.46M 114.87M 5.04M 22.93M

Quarterly Income Statements for AlloVir

This table shows AlloVir's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11 -12
Consolidated Net Income / (Loss)		 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11 -12
Net Income / (Loss) Continuing Operations		 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11 -12
Total Pre-Tax Income 		-60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11 -12
Total Operating Income		 -62 -2.56 -4.19 -38 -7.13 -10 -12 -13 -11 -12 -12
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 62 2.56 4.19 38 7.13 10 12 13 11 12 12
Selling, General & Admin Expense		 10 0.60 0.98 1.83 3.28 4.32 3.82 3.62 3.64 4.26 3.37
Research & Development Expense		 33 1.96 3.21 36 3.85 6.03 8.44 9.13 7.16 7.57 9.02
Total Other Income / (Expense), net		 2.58 -0.84 -1.46 -0.24 -15 0.19 0.91 0.85 0.80 0.98 0.87
Interest Expense		 - 0.08 0.50 0.82 1.31 - 0.00 - - 0.00 0.00
Other Income / (Expense), net		 1.21 -0.77 -0.96 0.58 -14 0.19 0.91 0.85 0.80 0.98 0.87
Basic Earnings per Share		 ($13.19) ($2.60) ($4.26) ($28.16) ($16.49) ($2.52) ($0.61) ($0.64) ($0.65) ($0.46) ($0.48)
Weighted Average Basic Shares Outstanding		 4.52M 1.31M 1.33M 1.35M 1.34M 4.05M 18.70M 18.70M 15.27M 23.72M 23.80M
Diluted Earnings per Share		 ($13.19) ($2.60) ($4.26) ($28.16) ($16.49) ($2.52) ($0.61) ($0.64) ($0.65) ($0.46) ($0.48)
Weighted Average Diluted Shares Outstanding		 4.52M 1.31M 1.33M 1.35M 1.34M 4.05M 18.70M 18.70M 15.27M 23.72M 23.80M
Weighted Average Basic & Diluted Shares Outstanding		 114.87M 115.00M 115.37M 115.54M 5.04M 18.70M 18.70M 18.70M 22.93M 23.79M 23.80M

Annual Cash Flow Statements for AlloVir

This table details how cash moves in and out of AlloVir's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 36 62 80 -96 -16 -1.53 97
Net Cash From Operating Activities		 -20 -61 -106 -142 -124 -21 -38
Net Cash From Continuing Operating Activities		 -20 -61 -106 -142 -124 -21 -38
Net Income / (Loss) Continuing Operations		 -24 -70 -172 -169 -190 -69 -43
Consolidated Net Income / (Loss)		 -24 -70 -172 -169 -190 -69 -43
Depreciation Expense		 0.02 0.07 0.19 0.72 0.40 0.00 0.01
Amortization Expense		 -0.62 0.50 1.20 -1.08 -3.70 0.00 -0.40
Non-Cash Adjustments To Reconcile Net Income		 2.89 9.73 45 43 67 53 3.25
Changes in Operating Assets and Liabilities, net		 1.39 -1.33 19 -16 2.03 -4.21 2.20
Net Cash From Investing Activities		 -65 -169 186 -80 38 0.00 -20
Net Cash From Continuing Investing Activities		 -65 -169 186 -80 38 0.00 -20
Purchase of Property, Plant & Equipment		 -0.34 -0.24 -0.03 0.00 - 0.00 -0.20
Purchase of Investments		 -119 -300 -77 -229 -126 0.00 -35
Sale and/or Maturity of Investments		 55 131 263 148 164 0.00 15
Net Cash From Financing Activities		 121 292 0.23 127 70 19 155
Net Cash From Continuing Financing Activities		 121 292 0.23 127 70 19 155
Repurchase of Common Equity		 0.00 -3.47 - - - 0.00 -1.67
Issuance of Debt		 - - - - - 20 7.50
Issuance of Preferred Equity		 121 0.00 - - - 1.59 0.00
Issuance of Common Equity		 0.00 295 0.00 127 70 0.00 50
Other Financing Activities, net		 - 0.00 0.23 0.00 - -2.42 99

Quarterly Cash Flow Statements for AlloVir

This table details how cash moves in and out of AlloVir's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -5.51 2.06 1.01 -4.33 -0.27 100 -13 -46 56 -64 8.75
Net Cash From Operating Activities		 -31 -4.52 -3.97 -4.33 -7.85 -7.44 -13 -11 -7.06 -12 -11
Net Cash From Continuing Operating Activities		 -31 -4.52 -3.97 -4.33 -7.85 -7.44 -13 -11 -7.06 -12 -11
Net Income / (Loss) Continuing Operations		 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11 -12
Consolidated Net Income / (Loss)		 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11 -12
Depreciation Expense		 0.14 - - - - 0.00 - - 0.01 0.01 0.01
Amortization Expense		 -1.21 - - - - 0.00 - - -0.32 -0.22 -0.11
Non-Cash Adjustments To Reconcile Net Income		 33 0.72 2.40 33 16 2.00 -0.64 0.65 0.01 0.62 0.64
Changes in Operating Assets and Liabilities, net		 -2.64 -1.83 -0.73 0.64 -2.29 0.75 -0.55 -0.01 3.24 -1.14 -0.07
Net Cash From Investing Activities		 25 0.00 - - - 0.00 - -35 15 -50 20
Net Cash From Continuing Investing Activities		 25 0.00 - - - 0.00 - -35 15 -50 20
Purchase of Investments		 -9.78 - - - - 0.00 - - - -70 0.17
Sale and/or Maturity of Investments		 35 - - - - 0.00 - - - 20 20
Net Cash From Financing Activities		 0.01 6.58 4.98 0.00 7.58 107 - - 48 -1.70 -0.38
Net Cash From Continuing Financing Activities		 0.01 6.58 4.98 0.00 7.58 107 - - 48 -1.70 -0.38
Other Financing Activities, net		 - -0.01 -0.02 0.00 -2.40 100 - - -0.59 -1.70 -0.38

Annual Balance Sheets for AlloVir

This table presents AlloVir's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 139 371 287 277 191 6.16 122
Total Current Assets		 127 361 253 243 188 2.61 119
Cash & Equivalents		 61 123 202 106 90 1.64 98
Short-Term Investments		 65 234 46 128 94 0.00 20
Prepaid Expenses		 0.68 4.54 5.18 9.10 3.49 0.97 0.83
Other Current Assets		 0.30 0.00 - - - - 0.00
Plant, Property, & Equipment, net		 0.35 0.81 1.55 0.93 0.00 0.00 0.00
Total Noncurrent Assets		 12 8.69 32 33 3.16 3.56 2.93
Long-Term Investments		 - - - - - - 0.00
Other Noncurrent Operating Assets		 12 8.69 32 33 3.16 3.56 2.93
Total Liabilities & Shareholders' Equity		 139 371 287 277 191 6.16 122
Total Liabilities		 18 18 61 53 45 57 43
Total Current Liabilities		 9.11 12 38 24 28 25 9.71
Accounts Payable		 0.88 1.54 10 3.00 6.76 1.56 1.28
Accrued Expenses		 5.16 7.53 20 14 10 2.20 8.12
Other Current Liabilities		 3.07 3.23 6.59 7.22 12 1.41 0.32
Total Noncurrent Liabilities		 8.69 5.46 23 28 17 32 33
Other Noncurrent Operating Liabilities		 8.69 5.46 23 - - 32 33
Commitments & Contingencies		 - - - - - 0.00 0.00
Total Equity & Noncontrolling Interests		 -52 353 225 225 146 -97 79
Total Preferred & Common Equity		 -52 353 225 225 146 -97 79
Total Common Equity		 -52 353 225 225 146 -97 79
Common Stock		 3.75 478 522 691 802 20 239
Retained Earnings		 -55 -125 -297 -466 -656 -117 -160
Accumulated Other Comprehensive Income / (Loss)		 0.07 -0.11 -0.16 -0.47 -0.06 0.00 0.01

Quarterly Balance Sheets for AlloVir

This table presents AlloVir's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 248 144 131 123 103 93 81 110 100
Total Current Assets		 220 141 130 123 102 92 78 98 96
Cash & Equivalents		 96 86 105 117 101 88 42 34 43
Short-Term Investments		 118 54 25 5.00 - - 35 63 50
Prepaid Expenses		 6.47 0.77 0.23 0.63 1.22 3.23 1.18 0.86 1.87
Other Current Assets		 - - - - - - - 0.39 0.51
Plant, Property, & Equipment, net		 0.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 28 2.66 1.05 0.00 0.91 1.19 2.99 11 3.62
Long-Term Investments		 - - - - - - - 7.65 0.00
Other Noncurrent Operating Assets		 28 2.66 1.05 0.00 0.91 1.19 2.99 3.69 3.62
Total Liabilities & Shareholders' Equity		 248 144 131 123 103 93 81 110 100
Total Liabilities		 53 24 11 1.41 39 40 39 41 42
Total Current Liabilities		 33 7.66 2.36 1.41 7.14 7.65 6.07 8.08 8.74
Accounts Payable		 3.93 0.77 0.11 0.05 2.37 3.68 0.49 0.91 1.12
Accrued Expenses		 16 4.60 1.58 1.36 4.40 3.97 5.20 6.86 7.27
Other Current Liabilities		 13 2.30 0.67 0.00 0.00 0.00 0.38 0.32 0.35
Total Noncurrent Liabilities		 20 16 8.34 0.00 32 32 33 33 33
Other Noncurrent Operating Liabilities		 20 16 8.34 0.00 32 32 33 33 33
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Total Equity & Noncontrolling Interests		 195 120 120 121 64 53 42 69 58
Total Preferred & Common Equity		 195 120 120 121 64 53 42 69 58
Total Common Equity		 195 120 120 121 64 53 42 69 58
Common Stock		 792 807 813 818 191 191 192 239 240
Retained Earnings		 -596 -686 -693 -697 -127 -138 -150 -171 -182
Accumulated Other Comprehensive Income / (Loss)		 -0.20 -0.14 -0.14 -0.13 - - 0.01 -0.05 -0.07

Annual Metrics And Ratios for AlloVir

This table displays calculated financial ratios and metrics derived from AlloVir's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 65,106,873.00 65,140,831.00 93,162,961.00 114,063,336.00 115,536,550.00 18,702,418.00
DEI Adjusted Shares Outstanding		 0.00 2,830,734.00 2,832,210.00 4,050,564.00 4,959,275.00 5,023,328.00 18,702,418.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -24.65 -60.72 -41.65 -38.40 -13.77 -2.32
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -166.13% -142.25% -0.19% -16.57% 66.70% 34.12%
EBIT Growth		 0.00% -174.53% -142.24% 0.82% -14.88% 66.14% 34.70%
NOPAT Growth		 0.00% -167.06% -138.14% -0.82% -16.76% 74.12% 10.79%
Net Income Growth		 0.00% -192.73% -146.42% 1.89% -12.87% 63.68% 37.20%
EPS Growth		 0.00% 86.03% -5.79% 19.71% -12.87% 63.68% 94.49%
Operating Cash Flow Growth		 0.00% -201.72% -74.84% -33.61% 12.39% 83.39% -85.63%
Free Cash Flow Firm Growth		 0.00% 0.00% -94.25% -62.82% 38.46% 74.86% -3.37%
Invested Capital Growth		 0.00% 26.79% -601.04% 182.90% -213.55% -52.06% -19.72%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -22.59% 8.85% -12.41% 38.46% 17.75%
EBIT Q/Q Growth		 0.00% 0.00% -22.14% 9.32% -12.46% 37.85% 16.39%
NOPAT Q/Q Growth		 0.00% 0.00% -21.79% 8.23% -12.35% 51.65% 17.87%
Net Income Q/Q Growth		 0.00% 0.00% -23.52% 10.51% -12.77% 35.26% 3.62%
EPS Q/Q Growth		 0.00% 0.00% -156.96% 21.43% -12.77% 35.26% -18.26%
Operating Cash Flow Q/Q Growth		 0.00% -25.16% -7.02% -2.53% 0.67% 52.54% 55.49%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -26.04% 15.31% 72.86% -423.97%
Invested Capital Q/Q Growth		 0.00% 0.00% -167.71% 274.12% -19.63% -4,363.17% -11.48%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -16,063.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -16,182.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -15,699.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -14,447.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.59% 99.84% 99.93% 100.00% 100.08%
Interest Burden Percent		 92.03% 98.13% 99.24% 98.90% 97.08% 104.06% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -19.60% -29.40% -59.47% -75.02% -102.85% -145.36% -308.10%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -853.17% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -18.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -17.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 8.30% -18.68% -59.47% -75.02% -102.85% -75.10% 194.52%
Return on Equity Simple (ROE_SIMPLE)		 46.29% -19.77% -76.34% -75.14% -130.62% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -50 -119 -120 -140 -36 -32
NOPAT Margin		 -11,327.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.08% -8.24% -17.57% -21.54% -27.08% -44.12% -22.25%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -86.15% 46.98% -40.99%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 6,435.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 9,847.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 16,282.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 -71 -172 -171 -196 -66 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -71 -171 -171 -200 -66 -44
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 7.09 3.74 2.13 0.53 0.00 2.00
Price to Tangible Book Value (P/TBV)		 0.00 7.09 3.74 2.13 0.53 0.00 2.00
Price to Revenue (P/Rev)		 1,674.24 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 14.38 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,959.39 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.13 0.11 -0.39 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.13 0.11 0.00 0.00
Financial Leverage		 -1.04 -1.02 -1.05 -1.01 -1.01 -1.57 -3.55
Leverage Ratio		 1.15 1.07 1.14 1.25 1.26 2.07 4.54
Compound Leverage Factor		 1.06 1.05 1.13 1.24 1.23 2.15 4.54
Debt to Total Capital		 0.00% 0.00% 0.00% 11.17% 10.25% -62.88% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -62.88% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 11.17% 10.25% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 142.35% 0.00% 0.00% 0.00% 0.00% -148.02% 0.00%
Common Equity to Total Capital		 -42.35% 100.00% 100.00% 88.83% 89.75% 310.90% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.16 -0.08 -0.29 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 1.20 0.84 -0.27 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.16 -0.08 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.24 -0.12 -0.54 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 1.72 1.20 -0.49 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.24 -0.12 0.00 0.00
Altman Z-Score		 9.16 84.59 5.71 2.01 -6.17 -65.87 0.27
Noncontrolling Interest Sharing Ratio		 142.35% 36.47% 0.00% 0.00% 0.00% 48.34% 163.13%
Liquidity Ratios		 - - - - - - -
Current Ratio		 13.98 29.39 6.69 9.99 6.61 0.11 12.23
Quick Ratio		 13.87 29.02 6.56 9.61 6.49 0.07 12.15
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -51 -99 -162 -99 -25 -26
Operating Cash Flow to CapEx		 -5,945.43% -25,877.02% -408,919.23% 0.00% 0.00% 0.00% -19,185.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -9.26 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -7.65 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -7.65 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.47 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -4.45 -3.26 -23 19 -22 -33 -39
Invested Capital Turnover		 -0.04 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.19 -20 42 -40 -11 -6.45
Enterprise Value (EV)		 323 2,146 595 272 -90 112 40
Market Capitalization		 276 2,503 843 478 78 49 158
Book Value per Share		 ($40.05) $5.42 $3.46 $2.41 $1.28 ($0.84) $4.21
Tangible Book Value per Share		 ($40.05) $5.42 $3.46 $2.41 $1.28 ($0.84) $4.21
Total Capital		 122 353 225 253 162 -31 79
Total Debt		 0.00 0.00 0.00 28 17 20 0.00
Total Long-Term Debt		 0.00 0.00 0.00 28 17 0.00 0.00
Net Debt		 -126 -356 -248 -206 -167 18 -118
Capital Expenditures (CapEx)		 0.34 0.24 0.03 0.00 0.00 0.00 0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.87 -7.30 -33 -15 -25 -4.20 -8.89
Debt-free Net Working Capital (DFNWC)		 118 349 215 219 159 -2.56 109
Net Working Capital (NWC)		 118 349 215 219 159 -22 109
Net Nonoperating Expense (NNE)		 5.15 20 53 49 50 33 11
Net Nonoperating Obligations (NNO)		 -126 -356 -248 -206 -167 18 -118
Total Depreciation and Amortization (D&A)		 -0.60 0.58 1.39 -0.35 -3.30 0.00 -0.39
Debt-free, Cash-free Net Working Capital to Revenue		 -4,769.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 71,640.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 71,640.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.59) ($2.74) ($2.20) ($42.09) ($11.73) ($2.85)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 65.11M 65.35M 76.65M 4.52M 5.01M 15.27M
Adjusted Diluted Earnings per Share		 $0.00 ($2.59) ($2.74) ($2.20) ($42.09) ($11.73) ($2.85)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 65.11M 65.35M 76.65M 4.52M 5.01M 15.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.59) ($2.74) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 26.90M 62.78M 93.46M 4.99M 5.04M 22.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -50 -119 -120 -127 -36 -32
Normalized NOPAT Margin		 -11,327.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -14,447.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -24.61 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -13.41 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -24.61 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -13.41 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -4.98% 0.00% 0.00% 0.00% 0.00% -3.84%

Quarterly Metrics And Ratios for AlloVir

This table displays calculated financial ratios and metrics derived from AlloVir's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 114,063,336.00 114,869,175.00 115,003,325.00 115,365,282.00 115,536,550.00 5,043,357.00 18,702,418.00 18,702,418.00 18,702,418.00 22,928,303.00 23,792,278.00
DEI Adjusted Shares Outstanding		 4,959,275.00 4,994,312.00 5,000,145.00 5,015,882.00 5,023,328.00 5,043,357.00 18,702,418.00 18,702,418.00 18,702,418.00 22,928,303.00 23,792,278.00
DEI Earnings Per Adjusted Shares Outstanding		 -12.04 -0.68 -1.13 -7.59 -4.38 -2.02 -0.61 -0.64 -0.53 -0.47 -0.48
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -54.76% 92.29% 89.09% 20.60% 66.73% -205.23% -120.35% 68.09% 50.26% -8.91% -2.37%
EBIT Growth		 -55.12% 92.17% 88.99% 18.62% 66.14% -205.23% -120.35% 68.09% 51.74% -6.84% -1.45%
NOPAT Growth		 -54.33% 94.07% 91.15% 19.40% 88.57% -303.98% -192.72% 66.34% -51.42% -14.28% -1.06%
Net Income Growth		 -56.53% 91.73% 87.52% 13.98% 63.10% -199.27% -100.89% 68.77% 54.61% -6.47% -1.45%
EPS Growth		 -56.53% 91.73% 87.52% 13.98% 63.10% 3.08% 85.68% 97.73% 96.06% 81.75% 21.31%
Operating Cash Flow Growth		 2.65% 85.92% 85.36% 87.45% 74.46% -64.59% -215.76% -161.91% 10.11% -55.64% 11.91%
Free Cash Flow Firm Growth		 95.40% 129.94% 63.50% -69.75% 292.58% 5.35% 257.80% 158.25% -117.84% -192.91% -146.61%
Invested Capital Growth		 -213.55% -122.28% 46.51% 95.92% -52.06% -84.62% -278.87% -4,693.18% -19.72% 2.10% -1.57%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -32.64% 94.65% -54.73% -623.53% 44.41% 50.95% -11.70% -4.79% 13.37% -7.40% -5.00%
EBIT Q/Q Growth		 -33.63% 94.56% -54.73% -623.53% 44.41% 50.95% -11.70% -4.79% 15.94% -8.58% -6.07%
NOPAT Q/Q Growth		 -32.89% 95.89% -63.36% -803.96% 81.15% -45.16% -18.37% -3.96% 15.23% -9.55% -4.67%
Net Income Q/Q Growth		 -34.84% 94.29% -65.84% -574.05% 42.16% 53.71% -11.32% -4.79% 15.94% -8.58% -6.07%
EPS Q/Q Growth		 -34.84% 94.29% -65.84% -574.05% 42.16% 84.72% 75.79% -4.92% -1.56% 29.23% -4.35%
Operating Cash Flow Q/Q Growth		 10.85% 85.29% 12.17% -8.97% -81.44% 5.22% -68.51% 9.62% 37.73% -64.11% 4.62%
Free Cash Flow Firm Q/Q Growth		 87.49% 387.20% -219.18% -296.46% 114.19% 57.11% 78.52% 46.35% -104.35% -718.10% 10.45%
Invested Capital Q/Q Growth		 -19.63% 6.62% 53.61% 92.14% -4,363.17% -13.38% 4.80% 0.50% -11.48% 7.29% 1.23%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.79% 100.00% 100.00% 100.00% 100.00% 100.34% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.76% 102.34% 109.69% 102.19% 106.32% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -102.85% -97.23% -64.70% -67.52% -145.36% -82.42% -82.19% -55.30% -308.10% -66.60% -79.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -102.85% -97.23% -64.70% -67.52% -75.10% -82.42% -82.19% -55.30% 194.52% -66.60% -79.91%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -126.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -44 -1.79 -2.93 -26 -4.99 -7.25 -8.58 -8.92 -7.56 -8.28 -8.67
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.59% -0.94% -1.45% -6.92% -22.80% -2.44% -2.54% -2.99% -4.87% -2.50% -3.13%
Return On Investment Capital (ROIC_SIMPLE)		 -26.89% -1.49% -2.44% -21.87% 6.48% -11.35% -16.15% -21.30% -9.59% -12.08% -15.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -61 -3.33 -5.15 -37 -21 -10 -11 -12 -10.00 -11 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -62 -3.33 -5.15 -37 -21 -10 -11 -12 -10 -11 -12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.53 0.72 0.69 0.77 0.00 0.63 0.94 2.58 2.00 1.93 1.68
Price to Tangible Book Value (P/TBV)		 0.53 0.72 0.69 0.77 0.00 0.63 0.94 2.58 2.00 1.93 1.68
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.11 0.00 0.00 0.00 -0.39 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.09 -1.08 -1.06 -1.57 -1.31 -1.26 -1.22 -3.55 -1.55 -1.64
Leverage Ratio		 1.26 1.24 1.18 1.17 2.07 1.34 1.29 1.25 4.54 1.61 1.74
Compound Leverage Factor		 1.24 1.27 1.30 1.20 2.20 1.34 1.29 1.25 4.54 1.61 1.74
Debt to Total Capital		 10.25% 0.00% 0.00% 0.00% -62.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% -62.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 10.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% -148.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 89.75% 100.00% 100.00% 100.00% 310.90% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.08 0.00 0.00 0.00 -0.29 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.84 0.00 0.00 0.00 -0.27 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.12 0.00 0.00 0.00 -0.54 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.20 0.00 0.00 0.00 -0.49 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -3.84 -3.43 -1.70 31.86 -41.37 -0.32 -0.65 -0.35 1.17 0.41 -0.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 48.34% 0.00% 0.00% 0.00% 163.13% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.61 18.48 55.08 86.78 0.11 14.31 11.98 12.89 12.23 12.19 10.98
Quick Ratio		 6.49 18.38 54.98 86.33 0.07 14.14 11.56 12.70 12.15 12.03 10.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.22 9.26 -11 -44 6.21 9.75 17 25 -1.11 -9.06 -8.12
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41,511.76% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 118.69 -22.11 -53.68 4.74 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -57.96 -7.96 -5.31 -6.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -57.96 -7.96 -5.31 -6.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -22 -20 -9.32 -0.73 -33 -37 -35 -35 -39 -36 -36
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -40 -11 8.10 17 -11 -17 -26 -34 -6.45 0.78 -0.56
Enterprise Value (EV)		 -90 -54 -46 -29 112 -60 -38 31 40 27 3.30
Market Capitalization		 78 87 83 93 49 40 50 108 158 132 97
Book Value per Share		 $1.28 $1.05 $1.05 $1.05 ($0.84) $12.67 $2.84 $2.24 $4.21 $2.89 $2.42
Tangible Book Value per Share		 $1.28 $1.05 $1.05 $1.05 ($0.84) $12.67 $2.84 $2.24 $4.21 $2.89 $2.42
Total Capital		 162 120 120 121 -31 64 53 42 79 69 58
Total Debt		 17 0.00 0.00 0.00 20 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -167 -141 -130 -122 18 -101 -88 -77 -118 -105 -94
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -25 -6.70 -2.03 -0.73 -4.20 -5.93 -4.43 -4.88 -8.89 -6.83 -6.36
Debt-free Net Working Capital (DFNWC)		 159 134 128 121 -2.56 95 84 72 109 90 87
Net Working Capital (NWC)		 159 134 128 121 -22 95 84 72 109 90 87
Net Nonoperating Expense (NNE)		 16 1.61 2.72 12 17 2.95 2.77 2.98 2.44 2.57 2.84
Net Nonoperating Obligations (NNO)		 -167 -141 -130 -122 18 -101 -88 -77 -118 -105 -94
Total Depreciation and Amortization (D&A)		 -1.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 -0.21 -0.10
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($303.37) ($5.98) ($1.15) ($0.92) ($379.27) ($2.52) ($0.61) ($0.64) ($0.65) ($0.46) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding		 196.71K 4.99M 5.01M 5.02M 58.08K 4.05M 18.70M 18.70M 15.27M 23.72M 23.80M
Adjusted Diluted Earnings per Share		 ($303.37) ($5.98) ($1.15) ($0.92) ($379.27) ($2.52) ($0.61) ($0.64) ($0.65) ($0.46) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding		 196.71K 4.99M 5.01M 5.02M 58.08K 4.05M 18.70M 18.70M 15.27M 23.72M 23.80M
Adjusted Basic & Diluted Earnings per Share		 ($303.37) $0.00 $0.00 $0.00 ($379.27) $0.00 $0.00 $0.00 ($0.65) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.99M 5.00M 5.02M 5.02M 219.28K 18.70M 18.70M 18.70M 22.93M 23.79M 23.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 -1.79 -2.93 -26 -4.99 -7.25 -8.58 -8.92 -7.56 -8.28 -8.67
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -42.68 -10.32 -45.73 -15.83 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -23.00 -5.87 -32.51 -3.81 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -42.68 -10.32 -45.73 -15.83 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -23.00 -5.87 -32.51 -3.81 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.84% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Kalaris Therapeutics (NASDAQ:KLRS) remains a pre-revenue biotechnology company with a persistent cash-burn profile. The company reported no revenue in the available quarterly income statements, and it has recorded a net loss in every period provided. In Q2 2026, the net loss widened to $11.5 million from $10.9 million in Q1 2026 and $10.0 million in Q4 2025, although it remained substantially below the unusually large losses reported in 2023 and parts of 2024.

Operating expenses increased to $12.4 million in Q2 2026, compared with $11.8 million in Q1 and $10.8 million in Q4 2025. Research and development spending was the largest component at $9.0 million, while selling, general and administrative expense was $3.4 million. The higher spending suggests continued investment in development programs, but it also indicates that profitability remains dependent on future clinical, regulatory or commercial milestones.

Liquidity is still the company’s primary financial strength. At June 30, 2026, KLRS held $43.2 million in cash and equivalents and $50.4 million in short-term investments, or approximately $93.5 million in liquid assets. However, Q2’s $8.7 million increase in cash was driven mainly by $20.0 million of investment maturities or sales, not by operations. Operating cash flow remained negative at $11.0 million, pointing to continued reliance on its investment portfolio and potential future financing.

  • Substantial liquidity: Cash and short-term investments totaled approximately $93.5 million at the end of Q2 2026, providing a financial cushion for ongoing development activities.
  • Improved operating loss compared with 2023 and early 2024: The Q2 2026 net loss of $11.5 million was well below the $59.7 million loss reported in Q4 2023 and the $38.1 million loss in Q3 2024.
  • Strong balance-sheet equity position: Total equity was $57.7 million at June 30, 2026, exceeding total liabilities of $41.9 million.
  • No revenue-related cost burden: With no reported revenue or cost of revenue, the company’s spending is concentrated primarily in research and development rather than operating a large commercial infrastructure.
  • Investment portfolio management supported near-term cash: The company generated $20.0 million from sales or maturities of investments in Q2 2026, but this is a balance-sheet liquidity action rather than recurring operating cash flow.
  • Interest and other income remain helpful but modest: Net other income was $871,000 in Q2 2026, partially offsetting operating expenses, but it is not sufficient to bring the company close to profitability.
  • Continued operating cash burn: Net cash used in operating activities was $11.0 million in Q2 2026, following $11.6 million in Q1 2026 and $12.5 million in Q2 2025.
  • No demonstrated commercial revenue: Revenue has been reported at zero across the available income statements, leaving the company dependent on financing, investment maturities and future product success.
  • Rising development spending: Research and development expense increased from $6.0 million in Q1 2024 to $9.0 million in Q2 2026, contributing to the recent increase in quarterly operating expenses.
  • Ongoing dilution and financing risk: Weighted-average basic shares increased from approximately 1.3 million in early 2024 to 23.8 million in Q2 2026, while the company continues to consume cash without operating revenue.

At the Q2 2026 operating cash-burn rate, the company’s roughly $93.5 million of cash and short-term investments represents several quarters of funding, before considering changes in spending, investment income, clinical costs or additional financing. Investors should also note that the supplied filings identify the underlying company as Allovir, Inc. even though the requested issuer is Kalaris Therapeutics, so the ticker and issuer identity should be independently verified before relying on these figures.

10/10/26 03:48 AM ETAI Generated. May Contain Errors.

AlloVir Financials - Frequently Asked Questions

According to the most recent income statement we have on file, AlloVir's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

AlloVir's net income appears to be on a downward trend, with a most recent value of -$43.44 million in 2025, falling from -$23.84 million in 2019. The previous period was -$69.17 million in 2024.

AlloVir's total operating income in 2025 was -$46.15 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $46.15 million

Over the last 6 years, AlloVir's total revenue changed from $165 thousand in 2019 to $0.00 in 2025, a change of -100.0%.

In the past 11 quarters, AlloVir's cash and equivalents has ranged from $34.43 million in Q1 2026 to $116.86 million in Q3 2024, and is currently $43.17 million as of their latest financial filing in Q2 2026.

AlloVir had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and none in 2019.

Over the last 6 years, AlloVir's book value per share changed from -40.05 in 2019 to 4.21 in 2025.


Related Companies

Financial statements for NASDAQ:ALVR last updated on 8/11/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...
Weiss Ratings | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel